Frontotemporal dementia (FTD) refers to a group of progressive neurodegenerative disorders with different pathological signatures, genetic variability and complex disease mechanisms. FTD overlaps clinically, genetically and pathologically with other early onset neurodegenerative conditions including Amyotrophic lateral sclerosis (ALS). Unfortunately, no effective treatments or therapeutics exist for FTD and there are no specific biomarkers that can accurately diagnose the underlying brain pathology during life. Both FTD and ALS are associated with TDP-43 pathology postmortem. In order to develop future treatments for FTD and ALS that targets TDP-43 pathology, it is vital to understand molecular mechanisms leading to abnormal aggregation of TDP-43 and subsequent neurodegeneration. This project will therefore investigate the role of the innate immune complement pathway underlying neuroinflammation and neurodegeneration in both FTD and ALS, in search for specific biomarkers and novel therapeutics. Furthermore, it will substantially advance the knowledge base within the FTD and ALS research communities with highly significant outcomes expected.
|Effective start/end date||3/02/20 → 2/02/23|